Roche responds to WHO’s declaration of a global health emergency due to the ongoing mpox outbreak

Roche is committed to supporting the global response to the mpox outbreak, which was declared a Public Health Emergency of International Concern by the WHO in August 2024. Roche provides access to high-quality PCR testing for mpox, including the cobas MPXV test and LightMix research use only kits, which detect all known variants of the virus. Roche is working to enhance laboratory testing capacity for mpox worldwide, particularly in Africa, by providing training and resources. The cobas MPXV test is an automated, real-time PCR test authorized by the FDA for use on cobas 6800/8800 Systems, ensuring accurate and reliable detection of mpox. The LightMix Modular Orthopox/Monkeypox Virus Kits are intended for research use in most countries and aid in epidemiological surveillance of the virus. Mpox, formerly known as monkeypox, is a viral disease that spreads between people and animals, causing symptoms such as fever, rash, and swollen lymph nodes. Roche has a long-standing commitment to developing innovative diagnostics and supporting global health efforts. Roche collaborates with governments, healthcare providers, and organizations to combat the mpox outbreak effectively. The company's diagnostic tests empower healthcare professionals to identify infected patients, enabling appropriate treatment and control measures. Roche's ongoing efforts aim to contribute to the global response to mpox, safeguarding public health and preventing further spread of the disease.